Table 2.
Clinical data of the study population
| Baseline | Month 3 | Month 6 | Month 9 | Month 12 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Latanoprost | Tafluprost | Latanoprost | Tafluprost | Latanoprost | Tafluprost | Latanoprost | Tafluprost | Latanoprost | Tafluprost | |
| Schirmer’s test, mm mean ± SD (CI 95%) | 16.6 ± 10.1 (13.3;19.9) | 16.8 ± 8.5 (13.8;19.7) | 15.9 ± 9.6 (12.7;19.1) | 15.7 ± 10.7 (12;19.4) | 18.1 ± 8.9 (15.1;21) | 14.3 ± 10.4 (10.6;17.9) | 17.8 ± 8.8 (14.9;20.7) | 17.8 ± 10.3 (14.2;21.4) | 18 ± 10.1 (14.6;21.4) | 16.9 ± 10.9 (13.1;20.7) |
| Break-up time, s mean ± SD (CI 95%) | 7.7 ± 4.2 (6.3;9.1) | 7.7 ± 3.1 (6.6;8.8) | 7.1 ± 2.8 (6.2;8) | 7.6 ± 2.6 (7;8.8) | 7.5 ± 2.5 (6.6;8.3) | 7.8 ± 2.9 (6.8;8.7) | 7.1 ± 2.9 (7.1;9) | 7.1 ± 2.7 (7.1;9) | 7.0 ± 3.7 (8.7;11.2) | 7.3 ± 3.1 (7.1;9.2) |
| Intraocular pressure mmHg mean ± SD (CI 95%) | 18.5 ± 5.4 (16.7;20.3) | 18.5 ± 4.5 (16.9;20) | 14.7 ± 2.2 (13.9;15.4) | 13.6 ± 2.5 (12.8;14.5) | 14.2 ± 2.4 (13.4;15) | 14.2 ± 2.7 (13.2;15.1) | 14.8 ± 1.8 (14.2;15.4) | 14.8 ± 2.3 (14;15.6) | 14.9 ± 1.7 (14.3;15.4) | 14.3 ± 3.1 (13.3;15.4) |
| Punctate keratitis, (yes/no) | 2/33 | 0/32 | 5/30 | 2/30 | 0/35 | 8/24 | 5/30 | 3/29 | 1/34 | 3/29 |
Inter-treatment and intra-treatment ANOVA (mixed-effect models) not significant
CI confidence interval, SD standard deviation